Long-acting IL-7 (NT-I7, efineptakin alfa) after CD19 CAR T-cell therapy for large B-cell lymphoma: a phase 1b trial. // Blood Immunology & Cellular Therapy. – URL: https://www.sciencedirect.com/science/article/pii/S305059762600062X?dgcid=rss_sd_all
Long-acting IL-7 (NT-I7, efineptakin alfa) after CD19 CAR T-cell therapy for large B-cell lymphoma: a phase 1b trial. Blood Immunology & Cellular Therapy. https://www.sciencedirect.com/science/article/pii/S305059762600062X?dgcid=rss_sd_all
“Long-acting IL-7 (NT-I7, efineptakin alfa) after CD19 CAR T-cell therapy for large B-cell lymphoma: a phase 1b trial.” Blood Immunology & Cellular Therapy.
@article{article38157,
title = {Long-acting IL-7 (NT-I7, efineptakin alfa) after CD19 CAR T-cell therapy for large B-cell lymphoma: a phase 1b trial},
journal = {Blood Immunology \& Cellular Therapy},
url = {https://www.sciencedirect.com/science/article/pii/S305059762600062X?dgcid=rss_sd_all}
}